Oncothyreon (ONTY) agrees to pay Array BioPharma (ARRY) $10M as part of a deal to collaborate on developing the latter's ARRY-380 molecule for treating breast and other cancers. Oncothyreon is raising the $10M by selling 5M shares and warrants for another 5M shares to BVF Partners.
From other sites
at CNBC.com (Feb 24, 2012)
at CNBC.com (Jun 24, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs